|
市場調査レポート
プロテオミクスを通じた治療薬・診断薬の開発
Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics
|
Abstract
Introduction
Genomics has paved the way for its cousin, proteomics, to secure its share of
the "omics" hype. Researchers look to proteomics to deliver on the promise to
assess the viability of drug targets for monitoring disease progression,
optimizing disease management, and diagnosing diseases with more precision.
While many challenges are inherent, given the complexities of protein-centric
science, technological improvements in the fi eld have resulted in important
gains for biopharma.
Get the Answers You Need to Shape Your Strategy
- Partnering in proteomics is slowing despite the potential of the
associated technologies to revolutionize drug discovery, diagnostics
development, and disease management. What problems are inherent in protein
biomarker research? What solutions have been developed to help overcome the
obstacles?
- Navigating the proteomics research process of preparation, separation,
identifi cation, and validation is complex. Which step is most critical
upstream to improve results downstream?
- Proteomics technologies give rise to a select set of protein biomarkers.
What are the differences between biomarkers for drug discovery and those for
diagnostics development?
Scope
- Proteomics technologies: 2DGE, MS, MALDI, SELDI, TOF, bioinformatics.
- Proteomics research process: Innovative methods of sample preparation,
separation and capture, identifi cation and analysis, and clinical validation.
- Companies with valuable insight into protein biomarker discovery:
20/20GeneSystems, Caprion Proteomics, NextGen BioSciences, Oxford
GlycoSciences.
- Outlook: Proteomics is approaching the long-awaited recognition that it
has the potential to deserve. Novel tools now in use will improve greatly
owing to collaborative initiatives that will stimulate innovation in protein research processes.
Table of Contents
Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Inherent Challenges in Researching Proteins
- Proving the Value of Proteomics
- Understanding the Proteomics Approach
- Sample Preparation
- Separation and Capture, Analysis and Identifi cation
- Planning Ahead for Clinical Validation
- Recent Perspectives on Proteomic Technologies
- Two-Dimensional Gel Electrophoresis
- Mass Spectrometry
- Bioinformatics Tools
- Biopharma Players in the Protein Research Arena
- Caprion Proteomics
- NextGen Sciences
- Power3 Medical Products
- Notable Initiatives in Proteomics
- Clinical Proteomic Technologies for Cancer
- Spectrum Expert Commentary
- Revitalizing Personalized Medicine Through Proteomics
- Improvements in Proteomics
- Protein Assay Platforms
- Spectrum Expert Commentary (cont.)
- Assay Availability
- At a Major Turning Point
- About the Author
- Human Plasma Proteome Project
- Outlook
- Overcoming Key Challenges
- Building Capacity Through Collaboration
Tables
- 1. Select Diagnostic Tests Based on Protein Biomarkers
- 2. Advantages and Disadvantages of 2DGE and MS Technologies
- 3. Select Protein Sequencing Databases
- 4. Select Proteomics Companies of Interest
- 5. Participants in the Clinical Proteomic Technologies for Cancer
Initiative
- 6. Pharmaceutical and Diagnostics Company Sponsors of the Human Plasma
Proteome Project
Figures
- 1. FDA Approval of NMEs Compared with R&D Spending, 2000-2008
- 2. Sensitivities and Specifi cities of Select FDA-Approved Protein
Biomarkers
- 3. Proteomics Research Process
- 4. Comparison of Protein Sample Sources
- 5. Number of Alliances Involving Proteomics, 2001-2008
Expert Commentary
- Revitalizing Personalized Medicine Through Proteomics
- M. Walid Qoronfl eh, Ph.D., M.B.A.,
- Vice President of Business Development at NextGen Sciences
|
